Share
In funding news this week: Kernal Biologics announced $25M Series A financing to advance its mRNA 2.0 technology for oncology ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

View in Browser »

Hi ,

I recently shared a video clip in my newsletter about my mum’s reaction to cultured meat. Today I’m sharing the full Leaps Talk from SynBioBeta 2022. I was joined by Niya Gupta, Co-founder and CEO of Fork & Good, Chef JJ Johnson, founder, TV personality, and author, and Amy Webb, CEO and Author at The Future Today Institute. Culture and cultures meat: Is the world ready for cell-to-table? Find out here.

These awesome SynBioBeta conference conversations would not be possible without sponsors like our good friends at Leaps by Bayer.

In funding news this week: Kernal Biologics announced $25M Series A financing to advance its mRNA 2.0 technology for oncology. The Cambridge, Massachusetts-based biotech aims to take mRNA beyond COVID-19 and vaccines with its in-development mRNA platform.

Spiderwort, a biotech company innovating in cellulose-based tissue scaffolding to treat acute spinal cord injuries, announced the completion of its $13.2 million Series A financing.

Congratulations to Charles Dimmler and the Checkerspot team for launching their first two snowboards featuring the award winning brand’s AlgalTech® materials derived from microalgae oil.

Congratulations to Jonny Ohlson (pictured below) and the Touchlight team for their patent license agreement with Pfizer to use enzymatic doggybone DNA to produce mRNA-based vaccines, therapeutics and gene therapies!

Congratulations to Ezhil Subbian (pictured below) and the String Bio team for their $20 million Series B raise. String Bio has built an innovative technology platform that leverages advances in biology, fermentation technology, chemistry and process engineering to convert the energy in methane into diverse value-added products.

The first healthy volunteers have been dosed in Synlogic's Phase 1 trial of SYNB1353, developed from their research collaboration with Ginkgo Bioworks. This step is taking them closer to developing a potential new treatment for patients with Homocystinuria (HCU).Congrats to Aoife Brennan (pictured below) and the team at Synlogic!

Phytolon and Biosyntia also just raised new rounds for the future of vitamins and sustainable food ingredients (see details below). You might have tried some of Phytolon’s samples in the SynBioBeta exhibit hall this year, congratulations to both companies! If you want to register for our 2023 summit, you can purchase an early bird ticket here. If you want to sponsor or exhibit, then please drop Anissa Cooke a note.

In other news: Birch Biosciences is participating in the Summer 2022 batch at Y Combinator. The company is engineering enzymes for plastic recycling using synthetic biology and machine learning, and their recycling process reduces carbon emissions and enables a circular plastic economy.

Our friends at Twist Bioscience just opened a new Boston location to expand their antibody discovery capacity.

I hope you have a great week.

Regards,
John

---

John Cumbers
Founder, SynBioBeta

Featured News

Biotech food colorant startup Phytolon seals $14.5M in funding

Phytolon, a developer of fermentation-based natural food colors, has secured $14.5 million in funding, led by DSM Venturing, to further progress its technology towards commercialization.

Keep Reading »

Biosyntia closes a €11.5M round to launch world’s first bio-based vitamin B7

A bio-based vitamin B7 is the first product to be commercialized as biotech company, Biosyntia, secures funding from a strong syndicate of capital investors.

Keep Reading »

Download the application note to learn how Inscripta’s Onyx® Digital Genome Engineering Platform can be used for rapid strain engineering to improve heterologous protein production.

Keep Reading »

Why Eric Schmidt believes bioscience will change the world

The bioeconomy is based on stuff that is grown using synthetic biology, such as "biologically neutral" cement that does not hurt the environment, and soil microbes that reduce fertilizer use.

Keep Reading »

Other News

Who's hiring?

Like our Digest? Please feel free to share with friends, family, and co-workers!


SynBioBeta, LLC
3559 Mount Diablo Boulevard #2, Lafayette, CA 94549

info@synbiobeta.com

If you no longer wish to receive our emails, you can unsubscribe here.
Modify Your Email Preferences


Email Marketing by ActiveCampaign